FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review on January 13, 2026 decision letter Hetlioz jet lag disorder NDA phase advance protocol rejection Supplement tasimelteon United States Food and Drug Administration Vanda Pharmaceuticals +
FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review on January 12, 2026 decision letter Hetlioz jet lag disorder NDA phase advance protocol rejection Supplement tasimelteon United States Food and Drug Administration Vanda Pharmaceuticals +
FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review on January 12, 2026 decision letter Hetlioz jet lag disorder NDA phase advance protocol rejection Supplement tasimelteon United States Food and Drug Administration Vanda Pharmaceuticals +
FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review on January 09, 2026 decision letter Hetlioz jet lag disorder NDA phase advance protocol rejection Supplement tasimelteon United States Food and Drug Administration Vanda Pharmaceuticals +
FDA again rejects Vanda’s Hetlioz for jet lag after yearslong dispute and ‘long‑shot’ re‑review on January 09, 2026 decision letter Hetlioz jet lag disorder NDA phase advance protocol rejection Supplement tasimelteon United States Food and Drug Administration Vanda Pharmaceuticals +